as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹254.46
Change
+4.17 (1.67%)
Open
₹250.55
Prev. Close
₹250.29
Day High
₹258.0
Day Low
₹244.2
Volume Analysis
Traded
100,085
Delivered
43,627
Delivery %
43.59%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (3)
- •High debt-to-equity ratio (1.16)
- •Low return on equity (-9.36%)
- •Below-average fundamentals quality score (42/100)
Opportunities (0)
No signal for this stock
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹274.04 | ₹266.02 | ₹260.24 | ₹252.22 | ₹246.44 | ₹238.42 | ₹232.64 |
| Fibonacci | ₹266.02 | ₹260.75 | ₹257.49 | ₹252.22 | ₹246.95 | ₹243.69 | ₹238.42 |
| Camarilla | ₹258.26 | ₹256.99 | ₹255.73 | ₹252.22 | ₹253.2 | ₹251.93 | ₹250.67 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+10.89%
1 Week
-1.22%
1 Month
+2.27%
3 Months
+6.37%
6 Months
+36.02%
1 Year
-10.97%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
DuPont ROE Breakdown
0.31%
Net margin 0.16% × asset turnover 0.71x × equity multiplier 2.76x
Company Overview
Sector
Healthcare
Market Cap
₹2,306 Cr
ROE
-9.36%
Book Value
₹102.0
Face Value
₹2.0
Source: Screener.in (Consolidated figures) — data as of 24 Sep 2026. Not investment advice.
TopFund Analysis
Indoco Remedies Ltd. scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 42/100. The strongest factor is Momentum (57/100), while Business Quality (24/100) is the weakest area to weigh before deciding. Notably: High debt-to-equity ratio (1.16); low return on equity (-9.36%).
TopFund Score — Fundamentals Quality
42/100 — WeakData confidence: 75/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company's working capital requirements have reduced from 40.8 days to 21.3 days
- −Company has low interest coverage ratio.
- −The company has delivered a poor sales growth of 8.25% over past five years.
- −Company has a low return on equity of -2.45% over last 3 years.
- −Earnings include an other income of Rs.98.3 Cr.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Crisil ESG Ratings assigned Indoco Remedies an ESG score of 60.
Indoco Remedies approved incorporation of wholly owned subsidiary Warren Lifesciences Pvt Ltd on 18 September 2026.
79th AGM voting results disclosed; shareholders approved final dividend, director reappointment, borrowing limit, and related resolutions.
UK MHRA inspected Goa Plant I from Sept 7-9, 2026; no critical or major observations.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 426 | 482 | 459 | 450 | 431 | 433 | 411 | 390 | 440 | 485 | 445 | 476 | 468 |
| Expenses + | 365 | 410 | 397 | 401 | 384 | 392 | 399 | 391 | 422 | 442 | 414 | 426 | 426 |
| Operating Profit | 61 | 71 | 63 | 49 | 48 | 40 | 12 | -1 | 18 | 43 | 32 | 50 | 41 |
| OPM % | 14.0% | 15.0% | 14.0% | 11.0% | 11.0% | 9.0% | 2.9% | -0.2% | 4.0% | 9.0% | 7.0% | 10.0% | 9.0% |
| Other Income + | 0 | 4 | -6 | 22 | 1 | 2 | 2 | 2 | 2 | 0 | -5 | 4 | 100 |
| Interest | 8 | 8 | 10 | 12 | 14 | 18 | 16 | 18 | 26 | 25 | 26 | 46 | 28 |
| Depreciation | 20 | 21 | 24 | 26 | 28 | 29 | 29 | 29 | 30 | 32 | 32 | 32 | 35 |
| Profit before tax | 34 | 46 | 23 | 33 | 7 | -5 | -31 | -46 | -37 | -14 | -31 | -25 | 78 |
| Tax % | 29.0% | 24.0% | 31.0% | 33.0% | 74.0% | 107.0% | -8.0% | -9.0% | -1.0% | -32.0% | -6.0% | -5.0% | 16.0% |
| Net Profit + | 24 | 35 | 16 | 22 | 2 | -10 | -28 | -41 | -36 | -9 | -29 | -24 | 65 |
| EPS in Rs | 3 | 4 | 2 | 2 | 0 | -1 | -3 | -4 | -4 | -1 | -3 | -2 | 7 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 854 | 1,005 | 1,071 | 1,041 | 968 | 1,107 | 1,242 | 1,541 | 1,669 | 1,817 | 1,665 | 1,845 | 1,873 |
| Expenses + | 689 | 834 | 914 | 906 | 892 | 983 | 1,017 | 1,213 | 1,381 | 1,572 | 1,565 | 1,703 | 1,708 |
| Operating Profit | 166 | 171 | 157 | 135 | 77 | 123 | 225 | 328 | 288 | 245 | 100 | 142 | 165 |
| OPM % | 19.0% | 17.0% | 15.0% | 13.0% | 8.0% | 11.0% | 18.0% | 21.0% | 17.0% | 13.0% | 6.0% | 8.0% | 9.0% |
| Other Income + | 2 | 1 | 4 | 5 | 6 | 2 | 3 | 2 | 1 | 20 | 6 | 0 | 98 |
| Interest | 11 | 12 | 6 | 24 | 21 | 26 | 22 | 14 | 25 | 38 | 66 | 122 | 124 |
| Depreciation | 47 | 61 | 63 | 68 | 72 | 71 | 73 | 79 | 71 | 92 | 114 | 126 | 131 |
| Profit before tax | 110 | 99 | 91 | 48 | -9 | 29 | 132 | 237 | 193 | 136 | -74 | -106 | 8 |
| Tax % | 24.0% | 17.0% | 15.0% | 15.0% | -69.0% | 16.0% | 30.0% | 35.0% | 26.0% | 29.0% | 5.0% | -7.0% | — |
| Net Profit + | 83 | 82 | 77 | 41 | -3 | 24 | 93 | 155 | 142 | 97 | -78 | -99 | 3 |
| EPS in Rs | 9 | 9 | 8 | 4 | 0 | 3 | 10 | 17 | 15 | 11 | -8 | -10 | 1 |
| Dividend Payout % | 18.0% | 18.0% | 19.0% | 22.0% | -95.0% | 11.0% | 15.0% | 13.0% | 15.0% | 14.0% | -2.0% | -2.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 500 | 558 | 633 | 657 | 642 | 661 | 751 | 886 | 1,010 | 1,091 | 1,004 | 921 |
| Borrowings + | 97 | 140 | 280 | 282 | 296 | 262 | 267 | 257 | 333 | 672 | 994 | 1,090 |
| Other Liabilities + | 230 | 224 | 266 | 281 | 301 | 330 | 279 | 325 | 297 | 363 | 414 | 564 |
| Total Liabilities | 846 | 941 | 1,197 | 1,238 | 1,258 | 1,272 | 1,315 | 1,486 | 1,658 | 2,145 | 2,430 | 2,593 |
| Fixed Assets + | 340 | 374 | 440 | 489 | 468 | 590 | 570 | 555 | 678 | 954 | 997 | 1,193 |
| CWIP | 63 | 55 | 91 | 136 | 185 | 51 | 68 | 122 | 114 | 125 | 321 | 90 |
| Investments | 0 | 16 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 9 | 1 | 1 |
| Other Assets + | 443 | 496 | 666 | 613 | 605 | 631 | 677 | 809 | 864 | 1,057 | 1,111 | 1,309 |
| Total Assets | 846 | 941 | 1,197 | 1,238 | 1,258 | 1,272 | 1,315 | 1,486 | 1,658 | 2,145 | 2,430 | 2,593 |
| Equity Capital | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 109 | 112 | 89 | 123 | 132 | 123 | 82 | 174 | 179 | 157 | 95 | 192 |
| Cash from Investing Activity + | -88 | -111 | -171 | -135 | -104 | -56 | -67 | -121 | -208 | -433 | -339 | -102 |
| Cash from Financing Activity + | -20 | -2 | 132 | -39 | -16 | -64 | -30 | -44 | 23 | 280 | 241 | -77 |
| Net Cash Flow | 1 | 0 | 50 | -51 | 12 | 3 | -14 | 8 | -7 | 4 | -3 | 14 |
| CFO/OP | 81 | 82 | 72 | 98 | 177 | 103 | 45 | 66 | 84 | 76 | 112 | 139 |
| Free Cash Flow | 20 | 15 | -100 | -15 | 39 | 64 | 6 | 49 | -27 | -269 | -257 | 91 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Others | 0.0% | 0.0% | 0.03% | 0.03% | 0.03% | 0.03% | 0.09% | 0.09% | 0.09% | 0.09% | 0.14% | 0.14% |
| Public | 21.87% | 20.0% | 19.92% | 21.07% | 21.27% | 21.02% | 21.02% | 20.82% | 21.6% | 21.76% | 21.9% | 22.04% |
| Promoters | 58.75% | 58.75% | 58.72% | 58.76% | 58.76% | 58.8% | 58.9% | 58.9% | 58.9% | 58.9% | 58.86% | 58.86% |
| FII | 1.59% | 1.69% | 1.92% | 1.48% | 1.7% | 1.25% | 1.24% | 1.22% | 1.25% | 1.1% | 0.94% | 1.27% |
| DII | 17.79% | 19.56% | 19.41% | 18.67% | 18.25% | 18.91% | 18.75% | 18.96% | 18.16% | 18.15% | 18.15% | 17.68% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Indoco Remedies Ltd. (this stock) | 2,306 | — | 2.45 | -9.36% |
| Fredun Pharmaceuticals L | 2,305 | 52.6 | 8.2 | 15.6% |
| Panacea Biotec Ltd | 2,282 | — | 2.74 | -2.42% |
| Windlas Biotech Limited | 2,274 | 34.2 | 4.01 | 12.2% |
| Venus Remedies Limited | 2,230 | 19.2 | 3.36 | 16.8% |
| Sai Parenterals Limited | 2,226 | 107.0 | — | 4.88% |
| Beta Drugs Limited | 2,400 | 52.6 | 8.98 | 18.8% |
Which Mutual Funds Hold Indoco Remedies Ltd.?
Frequently Asked Questions about Indoco Remedies Ltd.
Indoco Remedies Ltd. (INDOCO) closed at ₹254.46 on NSE on 25 September 2026, up 4.17 (1.67%) from the previous close.
Indoco Remedies Ltd. trades on the NSE (National Stock Exchange of India) under the symbol INDOCO.
Indoco Remedies Ltd. has a dividend yield of 0.08%.
Indoco Remedies Ltd.'s 52-week high is ₹317.0 and its 52-week low is ₹162.0.
Indoco Remedies Ltd. has a market capitalisation of ₹2,306 crore.
Indoco Remedies Ltd. has a TopFund Quality Score of 42/100 (Weak), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Indoco Remedies Ltd.?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.